Nodus Oncology, an Edinburgh, Scotland, UK-based biotech company focused on developing molecules that inhibit novel DNA damage response (DDR) targets, raised £2.4M in funding.
The round was led by KHAN Technology Transfer Fund I and Cumulus Oncology. Bert Klebl, Managing Director of KHAN-I will join the Board of Nodus Oncology.
The company intends to use the funds to accelerate the development of its PARG program in collaboration with the Lead Discovery Center GmbH (“LDC”), continue the development of novel DDR targets and further expand its portfolio.
Founded in September 2022 following the acquisition of Basilea Pharmaceutica’s PARG program, and led by Ian Waddell, CEO, Nodus focuses on the development of inhibitors against novel “third-wave” DDR targets, a new set of proteins that have recently been discovered and are thought to play important roles in the response to DNA damage.
FinSMEs
07/02/2023